

GP 1648

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.


BY: Martha O. Skunt

DATE: August 19, 1998

PATENT
BOX NON-FEE AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of James A. Hoxie : Group Art Unit: 1648
Appln. No.: 08/882,435 :
Filed: June 25, 1997 :
For: ANTIBODIES DIRECTED AGAINST : Attorney Docket
CELLULAR CORECEPTORS FOR : No. 9596-11U1
HUMAN IMMUNODEFICIENCY VIRUS : (I-1470)
AND METHODS OF USING THE SAME :



#128 9/6/98
T. Boy

RECEIVED
AUG 31 PAID
GROUP 1800

AMENDMENT

This Amendment responds to the Office Action dated May 22, 1998 (Paper No. 11), sent in connection with the above-referenced application. In response to the Office Action, kindly amend the application as follows.

In the Claims:

Please amend claim 1, without prejudice, as follows:

B' 1. (Amended) An anti-immunodeficiency virus antibody which binds to a [cellular protein] chemokine receptor protein essential for immunodeficiency virus entry into a cell wherein said chemokine receptor protein is not CD4.

Please cancel claim 3 without prejudice.

REMARKS

The invention relates to the discovery of a novel antibody which inhibits entry of HIV into cells and which specifically binds to a cellular chemokine receptor protein.

Claims 1-2 and 4-10 are pending in the application. Claim 3 has been canceled as being redundant in view of amended claim 1.